Revised Financial Result for the quarter ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Biocon (India) Ltd has filed a revised set of unaudited financial results for Q2 FY26 (quarter ended September 30, 2025) and H1 FY26. Sales in Q2 FY26 were nil (Rs. 0 lakh), compared with Rs. 473.69 lakh in Q2 FY25, and Rs. 166.57 lakh in the preceding Q1 FY26. For H1 FY26, total revenue fell to Rs. 166.57 lakh from Rs. 572.34 lakh a year ago — a drop of around 71%. The company slipped into a Q2 loss of Rs. 4.37 lakh (loss per share Rs. 0.02), though H1 FY26 remained marginally profitable at Rs. 9.49 lakh (EPS Rs. 0.04). The auditor (Mayur Shah & Associates) issued an unqualified limited review report with no concerns raised. Cash flow from operations was positive at Rs. 15.76 lakh for the half year, and the balance sheet remains debt-light with equity of Rs. 3,196.52 lakh against borrowings of just Rs. 18.21 lakh.
Shareholders should note the sharp revenue drop and the fact that results were revised from the earlier filing, which may raise governance questions despite the clean auditor report. The near-zero Q2 sales and the transition into a quarterly loss signal weak near-term operating momentum, though the small balance sheet and positive operating cash flow limit immediate solvency concerns.